APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in November:

  • Credit Suisse 30th Annual Healthcare Conference: Fireside chat on Wednesday, November 10, 2021 at 4:20 p.m. ET.

  • Stifel Healthcare Conference: Formal presentation on Monday, November 15, 2021 at 4:00 p.m. ET.

The conference events will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s . Replays of the webcasts will be available for 90 days following the event.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit .

Investor Contact:

Meredith Kaya



617.599.8178



EN
03/11/2021

Underlying

APLSApellis Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan inj...

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The results demonstrate that both every-other-month and monthly SYFOVRE delayed GA lesion growth by ap...

November 12, 2025 1 EN
Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
TVTX INC.
RZLT TRAVERE THERAPEUTICS INC
STX REZOLUTE
VERA SEAGATE TECHNOLOGY HLDGS PLC
GFS VERA THERAPEUTICS INC
ALCC GLOBALFOUNDRIES INC
DBD ALTC ACQUISITION CORP
MAZE DIEBOLD NIXDORF INCORPORATED
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
11/12/25 November 12, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
BIIB BIOGEN INC.
ARDX ARDELYX INC
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
VERA VERA THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
11/12/25 November 12, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
BIIB BIOGEN INC.
ARDX ARDELYX INC
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
11/07/25 November 7, 2025 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Confe...

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biop...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch